Veru appoints Louis Arrone as chief medical advisor for Enobosarm program

Veru announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator, to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist drug for potentially higher quality weight loss. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight Control Center, a state-of-the-art, multidisciplinary obesity research, education, and treatment center in the division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine.